# **1** Increased Expression of Colonic Mucosal Melatonin in Patients

# 2 with Irritable Bowel Syndrome Correlated with Gut Dysbiosis

- 3 Ben Wang<sup>1,#,a</sup>, Shiwei Zhu<sup>1,#,b</sup>, Zuojing Liu<sup>1,c</sup>, Hui Wei<sup>1,d</sup>, Lu Zhang<sup>1,e</sup>, Fei Pei<sup>2,f</sup>,
- 4 Meibo He<sup>3,g</sup>, Jindong Zhang<sup>1,h</sup>, Qinghua Sun<sup>1,i</sup>, Liping Duan<sup>1,\*,j</sup>
- <sup>5</sup> <sup>1</sup> Department of Gastroenterology, Peking University Third Hospital, Beijing 100191,
- 6 *China*
- 7 <sup>2</sup> Department of Pathology, School of Basic Medical Sciences, Peking University,
- 8 Beijing 100191, China
- 9 <sup>3</sup> Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking
- 10 University, Beijing 100191, China
- 11
- 12 # Equal contribution.
- 13 \* Corresponding Author.
- 14 Email: duanlp@bjmu.edu.cn (Duan LP)
- 15 **Running title:** Wang B et al / Increased Colonic Expression of Melatonin in IBS
- 16
- <sup>a</sup>ORCID: 0000-0001-5247-1531.
- 18 <sup>b</sup>ORCID: 0000-0002-2875-0706.
- 19 <sup>c</sup>ORCID: 0000-0002-1553-0050.
- <sup>d</sup>ORCID: 0000-0003-2568-9345.
- <sup>e</sup>ORCID: 0000-0002-9024-0432.
- <sup>f</sup>ORCID: 0000-0002-0842-9245.
- <sup>g</sup>ORCID: 0000-0003-1867-7901.
- <sup>h</sup>ORCID: 0000-0001-7478-140X.
- <sup>1</sup>ORCID: 0000-0001-5029-587X.
- <sup>j</sup>ORCID: 0000-0001-6886-6888.
- 27
- 28

29 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 30 Total word counts: 4292
- 31 Total figures: 7
- 32 Total tables: 2
- 33 Total supplementary figures: 8 Total supplementary tables: 4
- 34 The numbers of all references: 51 (the numbers of references from 2014: 28)

### 35 Abstract

Dysregulation of the gut microbiota/gut hormone axis contributes to the pathogenesis 36 of irritable bowel syndrome (IBS). Melatonin plays a beneficial role in gut motility 37 and immunity. However, altered expression of local mucosal melatonin in IBS and its 38 relationship with the gut microbiota remain unclear. Therefore, we aimed to detect the 39 colonic melatonin levels and microbiota profiles 40 in patients with diarrhea-predominant IBS (IBS-D) and explore their relationship in germ-free (GF) 41 rats and BON-1 cells. Thirty-two IBS-D patients and twenty-eight healthy controls 42 (HC) were recruited. Fecal specimens from IBS-D patients and HCs were separately 43 transplanted into GF rats by gavage. The levels of colon mucosal melatonin were 44 assessed by immunohistochemical methods, and fecal microbiota communities were 45 analyzed using 16S rDNA sequencing. The effect of butyrate on melatonin synthesis 46 in BON-1 cells was evaluated by ELISA. Melatonin levels were significantly 47 increased in IBS-D patients compared with HC and were significantly negatively 48 correlated with visceral sensitivity in IBS-D patients. GF rats inoculated with fecal 49 microbiota from IBS-D patients had high colonic melatonin 50 levels. 51 Butyrate-producing *Clostridium* cluster XIVa species, such as *Roseburia* species and Lachnospira species, were positively related to colonic mucosal melatonin expression. 52 Butyrate significantly increased melatonin secretion in BON-1 cells. Increased 53 54 melatonin expression may be an adaptive protective mechanism in the development of IBS-D. Moreover, some Clostridium cluster XIVa species could increase melatonin 55 expression via butyrate production. Modulation of the gut hormone/gut microbiota 56 57 axis offers a promising target of interest for IBS in the future.

58

59 KEYWORDS: Irritable bowel syndrome; Melatonin; Gut microbiota; Fecal
60 microbiota transplantation; Butyrate

61

## 62 Introduction

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disease that 63 considerably affects quality of life and work productivity [1]. Gut dysmotility, visceral 64 hypersensitivity, intestinal barrier dysfunction, immune activation, altered microbiota, 65 and brain-gut axis dysregulation may contribute to the development of IBS [2]. 66 Additionally, mast cells have been suggested as noteworthy players in the 67 68 pathophysiology of IBS [3]. Recently, gut hormones have attracted increasing attention in IBS development and aggravation. The secretion of cholecystokinin, 69 glucagon-like peptide 1, peptide YY, and serotonin differs between patients with 70 diarrhea-predominant IBS (IBS-D) and healthy controls (HC), which may contribute 71 to the pathogenesis of IBS and the maintenance of symptoms [4]. 72

73 Melatonin is widely found in nature [5,6]. In vertebrates, melatonin was first reported in the pineal gland. Subsequently, melatonin was also discovered in the 74 retina, Harderian gland, and gastrointestinal tract (GIT). Enterochromaffin cells in the 75 GIT mucosa have been shown to synthesize melatonin [7]. Accumulating evidence 76 77 has suggested the important roles and activities of melatonin in the GIT, especially 78 enteroprotective effects such as immunomodulatory activity, antioxidant effects, 79 maintenance of gastric prostaglandin levels and promotion of bicarbonate secretion [8-10]. Additionally, melatonin has also been reported to be involved in the 80 81 regulation of gut motility [11,12].

Given the importance of melatonin in gastrointestinal function, it is very likely that melatonin affects the pathophysiology of IBS. Some studies evaluated the effect of melatonin administration on IBS and found that it alleviates abdominal pain in IBS patients, but the mechanism remains unclear [13]. Therefore, exploration of the role of GIT melatonin in IBS is essential. However, the altered expression of local mucosal melatonin in IBS has not been evaluated to date.

Increasing evidence suggesting the effect of gut microbiota on the pathophysiology of IBS [14] and the importance of the gut microbiota/gut hormone axis in the pathogenesis of IBS has attracted increasing attention [4]. Additionally, a

91 recent study suggested that melatonin could alleviate lipid metabolism in high fat
92 diet-fed mice by modulating gut microbiota [15]. However, the association between
93 mucosal melatonin and gut microbiota remains obscure.

The aims of our study were (1) to detect colonic mucosal melatonin levels and gut dysbiosis in patients with IBS-D and (2) to further assess whether altered melatonin expression correlates with gut microbiota in humans, GF rats and BON-1 cells (a model of enterochromaffin cells [16]).

## 98 **Results and discussion**

### 99 Demographic and clinical characteristics of patients with IBS-D

Thirty-two IBS-D patients and twenty-eight HC were included. The demographic and 100 clinical characteristics are presented in **Table 1**. No significant differences in age, sex, 101 or body mass index (BMI) were found between the two groups. Anxiety and 102 depression scores were higher in patients with IBS-D, but the difference was not 103 significant. Protein, fat and carbohydrate intake was described as a proportion of total 104 energy consumption. No significant differences were found in the proportion of the 105 106 energy intake from protein, fat or carbohydrates between the two groups (Figure S1). 107 Twenty-eight IBS-D patients and seventeen HC underwent a rectal barostat test to evaluate visceral sensitivity, and the thresholds for sensation of defecation in IBS-D 108 patients were significantly lower than those in HC (Table 1). 109

# Increased melatonin expression was significantly negatively correlated with visceral sensitivity in IBS-D patients

112 Melatonin cell density was significantly higher in the colonic mucosa of IBS-D 113 patients (94.88  $\pm$  37.84/mm<sup>2</sup>) than in that of HC (73.61  $\pm$  31.19/mm<sup>2</sup>) (*P* = 0.0318) 114 (**Figure 1A, 1B, 1C**). The arylalkylamine N-acetyltransferase (AANAT, a 115 melatonin-synthesizing enzyme) cell density was also significantly increased in 116 IBS-D patients (33.23  $\pm$  24.34/mm<sup>2</sup>) compared to HC (24.50  $\pm$  21.63/mm<sup>2</sup>) (*P* = 117 0.0214) (**Figure 1D, 1E, 1F**).

118 To determine the role of melatonin in the GIT, it was necessary to determine 119 whether IBS-D patients exhibited dysregulated melatonin expression (particularly

mucosal melatonin expression), and this study was the first to evaluate the altered 120 expression of mucosal melatonin in IBS patients. Melatonin synthesized in the GIT 121 has been reported to be absorbed into the circulation and metabolized to 122 6-hydroxymelatonin sulfate (6-HMS) [17]. The 24-h urinary excretion of 6-HMS was 123 also reported to be higher in the IBS-D patients, which supports our finding [18]. 124 However, the results remain controversial. Another study reported the opposite results 125 and found that the 24-h urinary excretion of 6-HMS was higher in the HC group [19]. 126 127 Therefore, the alteration of gut melatonin may be a consequence rather than a cause according to the contradictory results regarding the melatonin metabolite 128 6-hydroxymelatonin sulfate in different studies. 129

To investigate the possible role of increased melatonin expression in IBS-D 130 patients, we performed Spearman correlation analyses between melatonin level and 131 visceral hypersensitivity in IBS-D patients. We found that the density of melatonin 132 cells was positively correlated with sensation thresholds of the urge to defecate and 133 maximal tolerable distension in IBS-D patients (Figure 1G, 1H, 1I, 1J), which 134 135 supported the idea that increased melatonin levels may be a countermeasure for the development of IBS. No correlation was found between the density of melatonin cells 136 and other parameters (psychological features and IBS Symptom Severity Scale 137 (IBS-SSS) scores) (Table 2). 138

Low-grade inflammation has been confirmed in the colonic mucosa of IBS and 139 mast cells are considered to play an essential role in mucosal inflammation [20]. In 140 the present study, the mast cell count was significantly higher in the colonic mucosa 141 of IBS-D patients (52.14  $\pm$  29.86/mm<sup>2</sup>) than in that of HC (16.42  $\pm$  12.01/mm<sup>2</sup>) (P = 142 0.000) (Figure 2A, 2B, 2C). Furthermore, mast cell counts were significantly 143 negatively associated with the threshold of maximal tolerable distension in patients 144 with IBS-D (Figure 2D, 2E, 2F, 2G). Numerous studies have suggested an increased 145 mast cell count in the colons of patients with IBS [21]. In addition, an increased mast 146 cell count and activation in the colons of patients with IBS may play an important role 147 in the pathophysiology of IBS, especially in visceral hypersensitivity [3,22]. All of 148 these findings are in line with our results 149

Moreover, melatonin has been confirmed to inhibit the activation and proliferation 150 of mast cells by in vitro and in vivo studies [23-25]. In our study, no significant 151 differences were detected between the densities of melatonin cells and mast cells (r =152 0.111, P = 0.567). Interestingly, when the mast cell counts were considered between 153 one standard deviation above the mean density of the HC  $(28.43 / mm^2)$  and nine 154 standard deviations below the mean density of the HC  $(124.51 / mm^2)$ , the density of 155 melatonin cells was significantly negatively correlated with the mast cell counts in 156 patients with IBS-D (r = -0.455, P = 0.038). In addition, accumulating evidence has 157 demonstrated the protective effects of melatonin on the GIT, including immune 158 enhancement, antioxidant activity, regulation of disturbed GI motility, visceral 159 sensitivity reduction, and anxiolytic and antidepressant activity [8]. Above all, the 160 elevated level of colonic mucosal melatonin in IBS-D patients may be based on an 161 adaptive mechanism to modulate the dysfunction of the GIT. 162

# 163 Transplantation of IBS-D patient fecal microbiota significantly elevated 164 melatonin expression in germ-free (GF) rats

165 To further explore the correlations between gut dysbiosis and melatonin observed in patients with altered expression, we performed fecal microbiota transplantation (FMT) 166 in male GF rats. We chose male GF rats for two reasons. First, estrogen in female rats 167 has been confirmed to be involved in the regulation of motor and sensory function in 168 the GIT and may confound the results [26]. Second, the gut microbiota has been 169 suggested to be influenced by estrogen; thus, the composition of gut microbiota may 170 be altered during the physiological cycle [27,28]. The density of melatonin cells in the 171 GI group (GF rats receiving fecal specimens from one IBS-D patient) (57.83  $\pm$  13.78 / 172 mm<sup>2</sup>) was significantly higher than that in the GH group (GF rats receiving fecal 173 specimens from one healthy control) (25  $\pm$  10.46 / mm<sup>2</sup>) and GN group (GF rats 174 without FMT) (20.2  $\pm$  6.26 / mm<sup>2</sup>) (Figure 3). The increased level of mucosal 175 melatonin expression indicates that abnormal gut flora results in abnormal melatonin 176 177 secretion in the colon via direct or indirect mechanisms.

178 The GF rats transplanted with the abnormal fecal microbiota from the IBS-D 179 patient also exhibited visceral hypersensitivity. Abdominal withdrawal reflex (AWR) scores were significantly higher in GI rats than in GH rats regardless of the pressure applied (from 20 to 80 mmHg) (Figure S2), which is in accordance with a previous study in which fecal microbiota from a single IBS patient were transferred to GF rats [29]. In the colonic mucosa specimens, the density of mast cells was higher in GI rats (118.2  $\pm$  64.02/mm<sup>2</sup>) than in GH rats (93.20  $\pm$  32.90/mm<sup>2</sup>) (Figure S3); however, this difference was not significant.

## 186 Gut dysbiosis was detected in IBS-D patients

187 Fecal samples from twenty-two IBS-D patients and eighteen HCs were collected for microbial analysis. The fecal microbiota richness in IBS-D patients was significantly 188 increased compared with that in HCs based on the ACE (246.78  $\pm$  84.07 versus 189 197.62  $\pm$  48.88, respectively; P = 0.035) and Chao (243.16  $\pm$  71.85 versus 198.36  $\pm$ 190 191 50.89, respectively; P = 0.032) richness indices. No significant differences in the Shannon (3.27  $\pm 0.60$  versus 3.08  $\pm 0.43$ , P = 0.33) or Simpson (0.10  $\pm 0.089$  versus 192  $0.11 \pm 0.058$ , P = 0.60) diversity indices were found between the two groups (Figure 193 S4, Table S1). There were 636 operational taxonomic units (OTUs) in the IBS-D 194 195 group and 524 OTUs in the HC group. In total, 463 OTUs coexisted in the two groups. The microbial community in the two groups could not be separated by principal 196 coordinates analysis (PCoA) (Figure S5), which may be due to the heterogeneity 197 within each group and the relatively small sample size. However, the partial least 198 squares-discriminant analysis (PLS-DA) revealed separation according to groups (HC 199 vs IBS-D) and was significantly different based on the cross-validation ANOVA 200 (CV-ANOVA) (P = 0.000321217) (Figure 4A). PLS-DA yielded a model with five 201 components with a cumulated index ( $Q^2 = 0.492$ ) that measures the overall goodness 202 of fit of the extremely high model explaining 98.1% ( $R^2Y$ ) of the variability between 203 the HC and IBS-D groups. An analysis of similarity (ANOSIM) (R = 0.0659, P =204 0.041, permutation number = 999) was also performed. A nonsignificant increase in 205 Firmicutes and a decrease in Bacteroidetes were found in the IBS-D group in this 206 study based on the community bar plot, which is in accordance with previous studies 207 [30,31] (Figure 4B). Moreover, the alteration in abundance of *Firmicutes* and 208 Bacteroidetes in patients with IBS has been shown in many studies, but the results 209

210 were controversial [32,33]. The reason for this discrepancy may be due to sample size, different DNA extraction methods and the various dietary habits of the recruited 211 subjects [34]. The abundance of *Prevotella\_9* was significantly increased in the IBS-D 212 group compared to the HC group based on the Wilcoxon rank-sum test at the genus 213 and species levels (Figure 4C, 4D). Prevotella has been reported to be enriched in 214 IBS-D patients and is suggested to be associated with a high risk of IBS-D [35]. The 215 enrichment and reduction in the observed bacterial communities in IBS-D patients are 216 217 displayed in a Manhattan plot (Figure 4E). The percentage of community abundance at the genus level in the two groups is shown in Table S2. 218

Additionally, no significant difference was found in the amount of fecal SCFAs (short-chain fatty acids; the main fermentation products of microbiota) between the two groups (Figure S6), which may be due to the following reasons. First, the content of fecal butyrate depends on production by bacterial fermentation and absorption in the colon. Second, the relatively small sample size may be a factor. The multifactorial determinants of fecal SCFAs may contribute to the inconsistent results.

## 225 Significant difference in gut microbiota in the GI and GH groups

The fecal microbiota richness in the GI group was remarkably higher than that in the 226 GH group based on the ACE (137.24  $\pm$  4.65 versus 94.26  $\pm$  8.59, respectively; P < 227 0.000), Shannon (3.17  $\pm$  0.12 versus 2.91  $\pm$  0.21, respectively; P = 0.028), and Chao 228  $(137.61 \pm 5.03 \text{ versus } 94.06 \pm 9.27, \text{ respectively; } P < 0.000)$  richness indices. There 229 were no significant differences in the Simpson (0.077  $\pm 0.012$  versus 0.095  $\pm 0.043$ , P 230 = 0.35) diversity index between the two groups (Figure S7, Table S3). The Venn 231 diagram showed 153 OTUs in the GI group and 113 OTUs in the GH group. In total, 232 233 91 OTUs appeared simultaneously in the two groups. A significant difference in 234 microbial composition was found between different groups by PCoA (Figure 5A). The abundance of Firmicutes was significantly enriched, and the abundance of 235 Bacteroidetes was significantly reduced in the GI group compared to the GH group 236 237 based on a community bar plot (Figure 5B).

238 The abundances of *Faecalibacterium*, *Roseburia*, and *Ruminococcus* were 239 significantly enriched, and the abundance of Bacteroides was significantly reduced in

the GI group based on the Wilcoxon rank-sum test at the genus and species levels (**Figure 5C, 5D**). The enrichment and reduction in the observed bacterial communities are displayed in a Manhattan plot (**Figure 5E**). The percentages of community abundances at the genus level in FMT rats are shown in Table S4.

The amounts of fecal formate, butyrate, valerate, and isovalerate were remarkably increased, and the amount of fecal propionate was remarkably reduced in the GI group compared with the GH group (Figure S8).

# Some butyrate-producing *Clostridium* cluster *XIVa* bacteria species were positively associated with colonic mucosal melatonin expression

As shown in the heat maps of Spearman rank correlation coefficients in humans, 249 Roseburia was significantly positively correlated with melatonin and AANAT 250 251 expression. Lachnospira and Parasutterella were significantly positively associated with AANAT expression (Figure 6A). Additionally, Roseburia and Lachnospira were 252 significantly positively related to fecal butyrate levels. The genus Roseburia, which 253 belongs to *Clostridium* cluster XIVa, consists of *Roseburia intestinalis*, *R. hominis*, *R.* 254 255 inulinivorans, R. faecis and R. cecicola [36]. The ability of Roseburia species to penetrate the mucus layer enables them to interact with gut epithelial cell surfaces and 256 exert physiological effects [37]. As SCFA producers, Lachnospira species also belong 257 to Clostridium cluster XIVa [38,39]. On the one hand, Clostridium cluster XIVa 258 species are known to be butyrate-producing bacteria and play a potential role in the 259 regulation of gut motility and innate immunity (mainly anti-inflammatory effects) [36, 260 40]. Butyrate has been confirmed to stimulate the expression of colonic serotonin (a 261 precursor of melatonin) in both in vivo and in vitro studies [41,42]. Moreover, 262 263 butyrate has been reported to promote melatonin expression in an intestinal epithelial 264 cell line (Caco-2 cells) [43], indicating that *Clostridium* cluster XIVa species may promote melatonin expression via butyrate. On the other hand, melatonin facilitates 265 goblet proliferation and MUC2 expression [44]. As mucin-adherent bacteria, 266 Clostridium cluster XIVa species compose 60% of mucosal microbiota, and 267 stimulating mucus production may lead to a higher abundance of mucin-adherent 268 bacteria [37]. Therefore, we postulate that melatonin could increase the abundance of 269

*Roseburia* and *Lachnospira* via the promotion of mucus secretion, in turn stimulating
melatonin expression and constituting a positive feedback loop.

In view of the correlation analyses in GF rats, most of the bacteria that positively correlated with melatonin expression belonged to *Clostridium* cluster XIVa such as *Roseburia*, *Lachnospiraceae*, *Blautia* and *Ruminiclostridium* species (**Figure 6B**), which is consistent with the results in humans. Furthermore, the changes in the abundance of butyrate-producing *Clostridium* cluster XIVa species (such as *Roseburia*) in IBS patients were not consistent among different studies [45,46] indicating that these changes may also be a consequence rather than a cause of the disease.

#### 279 Sodium butyrate promotes melatonin secretion in BON-1 cells

To confirm the effect of butyrate, one of the main metabolites of butyrate-producing 280 *Clostridium* cluster XIVa bacteria species, we used sodium butyrate to treat BON-1 281 cells and detected the melatonin concentration and AANAT expression in the treated 282 cells using ELISA and western blots, respectively. After treatment with sodium 283 butyrate for 24 h, the melatonin level was significantly increased in a dose-dependent 284 285 manner in BON-1 cells (Figure 7). The 10 mM sodium butyrate treatment group showed a significant increase in melatonin secretion compared with the untreated 286 control group and the 2.5 mM sodium butyrate-treatment group. The effect of butyrate 287 on AANAT was investigated by western blot assays. Treatment with 5 and 10 mM 288 sodium butyrate promoted AANAT expression in BON-1 cells, but the difference was 289 not significant. Therefore, butyrate could increase melatonin expression in a 290 dose-dependent manner according to our research, which was consistent with a 291 previous study [43]. Moreover, many studies have suggested that butyrate can 292 promote tight junction-mediated barrier integrity and exert anti-inflammatory 293 294 functions. Considering the protective effects of melatonin, the butyrate-melatonin link may be a protective mechanism of butyrate in IBS. 295

There were several limitations in this study. First, the present study involved only patients with IBS-D, and additional studies are needed to evaluate the alteration of melatonin in patients with other IBS subtypes. Second, cause and effect inference cannot be made based on our research. Further studies are needed to explore the

potential mechanisms underlying the association between gut microbiota and mucosalmelatonin.

In conclusion, our study is the first to demonstrate that melatonin expression is 302 increased in the colonic mucosa of IBS-D patients. Increased melatonin expression 303 may be an adaptive protective mechanism to reduce visceral hypersensitivity. Notably, 304 the study assessed the relationships between gut microbiota and melatonin expression 305 and suggested that different microbiota structures may contribute to different colonic 306 307 mucosal melatonin levels. Moreover, some butyrate-producing Clostridium cluster XIVa species, such as Roseburia and Lachnospira, could promote melatonin 308 expression via butyrate. These preliminary findings provide some clues for the 309 involvement of the dysregulated gut hormone/gut microbiota axis in the elusive 310 pathophysiology of IBS and in the search for new targeted approaches in the 311 312 treatment of IBS.

## 313 Methods and materials

#### 314 Subjects

315 Patients with IBS-D (aged 18-65 years) were enrolled from the gastroenterology 316 clinic of Peking University Third Hospital between March 2015 and January 2016 following the Rome III criteria [47]. Healthy volunteers without any symptoms (aged 317 18-65 years) were recruited by an Internet advertisement. The inclusion criteria were 318 319 as follows: 1) normal colonoscopy and 2) no abnormalities in routine blood or stool 320 exams or in liver or kidney function. The exclusion criteria were as follows: 1) organic gastrointestinal or systemic diseases, such as inflammatory bowel diseases or 321 diabetes mellitus; 2) current infectious diseases of the respiratory, digestive, or urinary 322 323 system; 3) a history of abdominal surgery; 4) history of antibiotic or probiotic use during the previous 4 weeks; 5) continuous laxative or antidiarrheal use for more than 324 325 3 days; 6) lactating or pregnant women; and 7) mental illness. Symptom severity was measured with the IBS-SSS. The severity of anxiety and depression symptoms was 326 evaluated with the Hospital Anxiety and Depression Scale (HADS). Eating habits 327 were investigated with a three-day dietary record sheet. Fecal samples were collected 328

329 for sequencing on the Illumina MiSeq platform. Visceral sensitivity was assessed by rectal barostat, as previously described in detail [48]; sensory thresholds for first 330 sensation, sensation of defecation, sensation of urge to defecate and maximal tolerable 331 distension were recorded as the lowest distention pressures (mmHg). All participants 332 underwent colonoscopy. Sigmoid colonic mucosal biopsies were obtained during 333 colonoscopy. The study was approved by the Ethics Committee of Peking University 334 Health Science Center (RB00001052-14091). Written informed consent was 335 336 obtained from all participants.

#### 337 Immunohistochemistry

Sections were cut with a Leica microtome at a thickness of 4 µm. The sections were 338 deparaffinized by following routine procedures. Rabbit anti-melatonin (abx100179, 339 1:800, Abbexa, Cambridge, UK), rabbit anti - AANAT (orb5712, 1:800, Biorbyt, 340 Wuhan, China), and anti-mast cell tryptase (ab2378, 1:3000, Abcam, Cambridge, UK) 341 primary antibodies were used to detect melatonin, AANAT, and mast cells, 342 respectively. A horseradish peroxidase/3,3' - diaminobenzidine detection system 343 344 (PV-6000, PV-6001, Zhongshan Golden Bridge, Beijing, China) was used for visualization. 345

For the quantification of melatonin and AANAT expression, ten fields were 346 randomly selected at a magnification of x400 from each slide under a Leica DM 2500 347 microscope (LEICA Microsystems, Germany), captured using a Nikon DS-Vi1 348 camera (Nikon Instruments, China), and exported by the Nikon NIS-Elements 349 350 imaging software. The number of immunoreactive cells was counted in every field 351 and the area of every field was calculated using Image-Pro Plus 6.0 software (Media 352 Cybernetics, Inc., USA). To quantify mast cells, the NanoZoomer-SQ digital slide 353 scanner (Hamamatsu Photonics, Japan) was used for whole slide scanning, and three randomly selected fields at a magnification of x400 were exported by NDP view2 354 viewing software (Hamamatsu Photonics, Japan). The density of immunoreactive 355 356 cells was expressed as the average number of cells per square millimeter of mucosal epithelium. 357

#### 358 **DNA extraction of fecal microbiota**

Microbial DNA was extracted from fecal samples with an E.Z.N.A.® Soil DNA Kit 359 Bio-Tek, Norcross, GA. USA). Two 360 (Omega primers [338F 806R 361 (5'-ACTCCTACGGAGGCAGCAG-3') and (5'-GGACTACHVGGGTWTCTAAT)] were used to amplify the hypervariable 362 regions (V3 to V4) of the bacterial 16S ribosomal RNA gene. Polymerase chain 363 reaction was performed with the following program: 3 min of denaturation at 95C; 27 364 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 45 s; and a final extension at 365 366  $72 \, \text{C}$  for 10 min. Purified amplicons were pooled in equimolar amounts, and paired-end sequencing (2x300) was performed on the Illumina MiSeq platform 367 (Illumina, San Diego, CA, USA). 368

## 369 Processing of sequencing data

Trimmomatic was used to demultiplex and quality-filter raw FASTQ files and raw FASTQ files were merged by fast length adjustment of short reads (FLASH). OTU clustering was performed by UPRISE (version 7.0 http://drive5.com/uparse/). Chimeric sequences were identified and removed by UCHIME. The taxonomy of each 16S rRNA gene sequence analysis was performed using the RDP Classifier algorithm against the Silva (SSU128) 16S rRNA database with confidence threshold of 70%.

#### 377 Quantification of fecal SCFAs

Ultra-performance liquid chromatography coupled with tandem mass spectrometry
(UPLC-MS/MS) was used to determine the levels of SCFAs (formate, acetate,
propionate, butyrate, isobutyrate, valerate, and isovalerate acetate) in feces as
previously described [49].

#### 382 Animal experiments

Male germ-free (GF) Sprague-Dawley (SD) rats were obtained from the Department of Laboratory Animal Science at Peking University Health Science Center. GF rats were divided into three groups and housed in separated sterilized isolators. Different groups of GF rats were maintained in different sterile bubbles, and every GF rat was housed in a separate cage to avoid cage effects. A total of 16 GF rats (6 in the GI group, 5 in the GH group, and 5 in the GN group) were used in this study. At six

weeks of age, GF rats in different groups were subjected to fecal microbiota 389 transplantation [obtained from one IBS-D patient (GI group) and one healthy control 390 (GH group)] separately by gavage. Rats in the same group received fecal microbiota 391 from the same sample, and transplantation was performed only once. Two weeks after 392 FMT, fecal samples were collected from the rats for further microbiota analyses. 393 Colorectal distension (CRD) tests were performed 24 days after FMT as described 394 previously [48]. Then, GF rats were sacrificed with anesthesia. Colon tissue was fixed 395 396 in 10% buffered formalin for immunohistochemistry. All protocols were approved by the Laboratory Animal Welfare Ethics branch of the Biomedical Ethics Committee of 397 Peking University (LA2016230). 398

## 399 Cell culture

BON-1 cells were purchased from Shanghai Shun Ran Biotechnology Co., Ltd. and
cultured in DMEM (SH30022.01, HyClone, Utah, USA) supplemented with 10%
FBS (900-108, Gemini, California, USA) and 1% penicillin/streptomycin (15140122,

Gibco, Massachusetts, USA) at 37 °C in a humidified atmosphere of 5% CO2. Cells
were subcultured every 2 days.

#### 405 Melatonin measurements

Cells were seeded in 60-mm dishes, allowed to attach and treated with sodium butyrate (303410, Sigma-Aldrich, USA) at concentrations ranging from 0 to 10 mM for 24 h. Then, supernatants were harvested and melatonin levels were determined with an ELISA kit (E-EL-H2O16c, Elabscience, Wuhan, China). Readings were normalized to total protein content, which was detected using a BCA assay. The data compiled from different treatment groups were expressed as melatonin concentrations normalized to the untreated control group.

#### 413 Western blot analysis

414 Proteins from BON-1 cells were extracted with RIPA extraction buffer mixed with a 415 protease inhibitor cocktail. Equal amounts of protein (30 μg) were electrophoresed in 416 12% sodium dodecyl sulfate polyacrylamide gels and transferred onto nitrocellulose 417 membranes under a constant current of 250 mA for 90 min. The membranes were 418 incubated with rabbit anti-AANAT antibody (1:1,000, ab3505, Abcam, Cambridge,

419 UK) overnight at 4 °C.  $\beta$ -actin was chosen as the internal reference protein. The 420 primary antibodies were detected using anti-rabbit or mouse secondary antibodies and 421 were visualized with an infrared imaging system (LI-COR Biosciences, Lincoln, 422 USA). The band intensity relative to that of  $\beta$ -actin was calculated, and the results 423 were expressed as fold change from control values.

424 Statistical analysis

The mean number of melatonin and AANAT immunoreactive cells per square 425 millimeter of mucosal epithelium was compared using the nonparametric 426 Mann-Whitney test (between IBS-D patients and HC) and Kruskal-Wallis 427 nonparametric test with posttest (among different GF rats). The differences in age and 428 BMI were analyzed by independent samples t-test. The  $\chi^2$  test or Fisher's exact test 429 was used to detect sex differences between IBS-D patients and HC. Correlations 430 between melatonin and clinical and experimental parameters were explored using 431 Spearman's rank correlation analysis. The statistical analyses were performed using 432 SPSS software version 24.0 (SPSS Inc., Chicago, IL, USA). Alpha diversity based on 433 434 the OTU table was analyzed with the abundance-based coverage estimator (ACE), the Chao1 estimator (Chao), and the Shannon and Simpson diversity indices in Mothur 435 (version v.1.30.1).  $\beta$ -Diversity was calculated using UniFrac distance, and PCoA was 436 performed in R (version 3.3.1) to visualize the difference in community composition 437 among different groups. PLS-DA and CV-ANOVA were performed using SIMCA 438 (version 14.1.0). The associations among the expression levels of melatonin, AANAT, 439 SCFAs (acetate, propionate, butyrate) and bacterial taxa were visualized and 440 identified by heat maps of Spearman rank correlation coefficients using the pheatmap 441 442 package in R (version 3.3.1). One-way analysis of variance (ANOVA) with post hoc testing was conducted using SPSS to determine differences in melatonin secretion 443 according to ELISA among different treatment groups. 444

445

#### 446 **Data availability**

447 The raw sequence data have been uploaded to the Genome Sequence Archive [50] in

BIG Data Center [51] under accession number CRA001604 and are publicly
accessible at <a href="http://bigd.big.ac.cn/gsa">http://bigd.big.ac.cn/gsa</a>.

450

## 451 Author contributions

452 DL and WB designed the study; ZS, IZ, WH, ZL, SQ and WB recruited the IBS-D 453 patients and HC. WB, ZS, IZ, WH, ZL, ZJ and SQ acquired data; WB drafted the 454 initial manuscript; WB, ZS and HM analyzed and interpreted the data; HM and PF 455 provided technical support; and DL revised the manuscript critically. All authors 456 approved the final version of the manuscript.

## 457 **Competing interests**

458 The authors have declared no competing interests.

459

## 460 Acknowledgments

This study was supported by the National Natural Science Foundation of China 461 462 (81670491) and the Capital Health Research and Development of Special Program (2016-2-4093). The authors are grateful to all subjects participating in this study. The 463 authors appreciate the technical support of the Medical Research Center of Peking 464 University Third Hospital and the Clinical Stem Cell Center of Peking University 465 Third Hospital. The authors appreciate the support of the Department of Laboratory 466 Animal Science, Peking University Health Science Center with the animal 467 experiments. The authors appreciate the assistance of the Institute of Acupuncture and 468 Moxibustion China Academy of Chinese Medical Sciences for the CRD tests in rats. 469 470 The authors appreciate the technical assistance of Professor Ence Yang (Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University) and 471 Professor Xiaoli Wang (School of Public Health, Peking University). 472

## 473 **References:**

- 474 [1] Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review.
- 475 JAMA 2015;313:949-58.
- 476 [2] Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel
- 477 Disorders. Gastroenterology 2016.
- 478 [3] Zhang L, Song J, Hou X. Mast Cells and Irritable Bowel Syndrome: From the
- 479 Bench to the Bedside. J Neurogastroenterol Motil 2016;22:181-92.
- 480 [4] Fukui H, Xu X, Miwa H. Role of Gut Microbiota-Gut Hormone Axis in the
- 481 Pathophysiology of Functional Gastrointestinal Disorders. J Neurogastroenterol Motil
- 482 2018;24:367-86.
- 483 [5] Hardeland R, Poeggeler B. Non-vertebrate melatonin. J Pineal Res

484 2003;34:233-41.

- [6] Mukherjee S, Maitra SK. Gut Melatonin in Vertebrates: Chronobiology and
- 486 Physiology. Front Endocrinol (Lausanne) 2015;6:112.
- 487 [7] Bubenik GA. Thirty four years since the discovery of gastrointestinal melatonin. J
- 488 Physiol Pharmacol 2008;59 Suppl 2:33-51.
- 489 [8] Mozaffari S, Rahimi R, Abdollahi M. Implications of melatonin therapy in
- 490 irritable bowel syndrome: a systematic review. Curr Pharm Des 2010;16:3646-55.
- 491 [9] Sjoblom M, Jedstedt G, Flemstrom G. Peripheral melatonin mediates neural
- 492 stimulation of duodenal mucosal bicarbonate secretion. J Clin Invest
- 493 2001;108:625-33.
- 494 [10] Sommansson A, Saudi WS, Nylander O, Sjoblom M. Melatonin inhibits
- 495 alcohol-induced increases in duodenal mucosal permeability in rats in vivo. Am J
- 496 Physiol Gastrointest Liver Physiol 2013;305:G95-G105.
- 497 [11] Harlow HJ, Weekley BL. Effect of melatonin on the force of spontaneous
- 498 contractions of in vitro rat small and large intestine. J Pineal Res 1986;3:277-84.
- 499 [12] Barajas-Lopez C, Peres AL, Espinosa-Luna R, Reyes-Vazquez C, Prieto-Gomez
- 500 B. Melatonin modulates cholinergic transmission by blocking nicotinic channels in
- the guinea-pig submucous plexus. Eur J Pharmacol 1996;312:319-25.

- 502 [13] Siah KT, Wong RK, Ho KY. Melatonin for the treatment of irritable bowel
- 503 syndrome. World J Gastroenterol 2014;20:2492-8.
- 504 [14] Dupont HL. Review article: evidence for the role of gut microbiota in irritable
- 505 bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol
- 506 Ther 2014;39:1033-42.
- 507 [15] Yin J, Li Y, Han H, Chen S, Gao J, Liu G, et al. Melatonin reprogramming of gut
- 508 microbiota improves lipid dysmetabolism in high-fat diet-fed mice. J Pineal Res
- 509 2018;65:e12524.
- 510 [16] Kim M, Cooke HJ, Javed NH, Carey HV, Christofi F, Raybould HE. D-glucose
- 511 releases 5-hydroxytryptamine from human BON cells as a model of enterochromaffin
- 512 cells. Gastroenterology 2001;121:1400-6.
- 513 [17] Huether G, Poeggeler B, Reimer A, George A. Effect of tryptophan
- administration on circulating melatonin levels in chicks and rats: evidence for
- stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci
- 516 1992;51:945-53.
- 517 [18] Wisniewska-Jarosinska M, Chojnacki J, Konturek S, Brzozowski T, Smigielski J,
- 518 Chojnacki C. Evaluation of urinary 6-hydroxymelatonin sulphate excretion in women
- at different age with irritable bowel syndrome. J Physiol Pharmacol 2010;61:295-300.
- 520 [19] Radwan P, Skrzydlo-Radomanska B, Radwan-Kwiatek K, Burak-Czapiuk B,
- 521 Strzemecka J. Is melatonin involved in the irritable bowel syndrome? J Physiol
- 522 Pharmacol 2009;60 Suppl 3:67-70.
- 523 [20] Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, et al. Mast cell number,
- substance P and vasoactive intestinal peptide in irritable bowel syndrome with
- diarrhea. Scand J Gastroenterol 2014;49:43-51.
- 526 [21] Bashashati M, Moossavi S, Cremon C, Barbaro MR, Moraveji S, Talmon G, et al.
- 527 Colonic immune cells in irritable bowel syndrome: A systematic review and
- 528 meta-analysis. Neurogastroenterol Motil 2018;30.
- 529 [22] Yang CQ, Wei YY, Zhong CJ, Duan LP. Essential role of mast cells in the
- visceral hyperalgesia induced by T. spiralis infection and stress in rats. Mediators
- 531 Inflamm 2012;2012:294070.

- 532 [23] Izzo G, d'Istria M, Serino I, Minucci S. Inhibition of the increased
- 533 17beta-estradiol-induced mast cell number by melatonin in the testis of the frog Rana
- esculenta, in vivo and in vitro. J Exp Biol 2004;207:437-41.
- 535 [24] Maldonado MD, Garcia-Moreno H, Gonzalez-Yanes C, Calvo JR. Possible
- 536 Involvement of the Inhibition of NF-kappaB Factor in Anti-Inflammatory Actions
- 537 That Melatonin Exerts on Mast Cells. J Cell Biochem 2016;117:1926-33.
- 538 [25] Calvo JR, Gonzalez-Yanes C, Maldonado MD. The role of melatonin in the cells
- of the innate immunity: a review. J Pineal Res 2013;55:103-20.
- 540 [26] Mulak A, Tache Y, Larauche M. Sex hormones in the modulation of irritable
- bowel syndrome. World J Gastroenterol 2014;20:2433-48.
- 542 [27] Huang G, Xu J, Lefever DE, Glenn TC, Nagy T, Guo TL. Genistein prevention
- of hyperglycemia and improvement of glucose tolerance in adult non-obese diabetic
- 544 mice are associated with alterations of gut microbiome and immune homeostasis.
- 545 Toxicol Appl Pharmacol 2017;332:138-48.
- 546 [28] Sasaki H, Kawamura K, Kawamura T, Odamaki T, Katsumata N, Xiao JZ, et al.
- 547 Distinctive subpopulations of the intestinal microbiota are present in women with
- unexplained chronic anovulation. Reprod Biomed Online 2019;38:570-8.
- [29] Crouzet L, Gaultier E, Del'Homme C, Cartier C, Delmas E, Dapoigny M, et al.
- 550 The hypersensitivity to colonic distension of IBS patients can be transferred to rats
- through their fecal microbiota. Neurogastroenterol Motil 2013;25:e272-82.
- 552 [30] Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, et
- al. Global and deep molecular analysis of microbiota signatures in fecal samples from
- patients with irritable bowel syndrome. Gastroenterology 2011;141:1792-801.
- [31] Nagel R, Traub RJ, Allcock RJ, Kwan MM, Bielefeldt-Ohmann H. Comparison
- of faecal microbiota in Blastocystis-positive and Blastocystis-negative irritable bowel
- 557 syndrome patients. Microbiome 2016;4:47.
- [32] Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J, et al.
- 559 Identification of an Intestinal Microbiota Signature Associated With Severity of
- 560 Irritable Bowel Syndrome. Gastroenterology 2017;152:111-23 e8.
- 561 [33] Jalanka-Tuovinen J, Salojarvi J, Salonen A, Immonen O, Garsed K, Kelly FM, et

- al. Faecal microbiota composition and host-microbe cross-talk following
- 563 gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014;63:1737-45.
- 564 [34] Rodino-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-Garcia R, Santos J. A
- 565 Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther
- 566 2018;35:289-310.
- 567 [35] Su T, Liu R, Lee A, Long Y, Du L, Lai S, et al. Altered Intestinal Microbiota
- 568 with Increased Abundance of Prevotella Is Associated with High Risk of
- 569 Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterol Res Pract
- 570 2018;2018:6961783.
- 571 [36] Tamanai-Shacoori Z, Smida I, Bousarghin L, Loreal O, Meuric V, Fong SB, et al.
- 572 Roseburia spp.: a marker of health? Future Microbiol 2017;12:157-70.
- 573 [37] Van den Abbeele P, Belzer C, Goossens M, Kleerebezem M, De Vos WM, Thas
- 574 O, et al. Butyrate-producing Clostridium cluster XIVa species specifically colonize
- 575 mucins in an in vitro gut model. ISME J 2013;7:949-61.
- [38] Collins MD, Lawson PA, Willems A, Cordoba JJ, Fernandez-Garayzabal J,
- 577 Garcia P, et al. The phylogeny of the genus Clostridium: proposal of five new genera
- and eleven new species combinations. Int J Syst Bacteriol 1994;44:812-26.
- 579 [39] Lopetuso LR, Scaldaferri F, Petito V, Gasbarrini A. Commensal Clostridia:
- leading players in the maintenance of gut homeostasis. Gut Pathog 2013;5:23.
- [40] Patterson AM, Mulder IE, Travis AJ, Lan A, Cerf-Bensussan N,
- 582 Gaboriau-Routhiau V, et al. Human Gut Symbiont Roseburia hominis Promotes and
- 583 Regulates Innate Immunity. Front Immunol 2017;8:1166.
- [41] Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous
- bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell
- 586 2015;161:264-76.
- 587 [42] Reigstad CS, Salmonson CE, Rainey JF, 3rd, Szurszewski JH, Linden DR,
- 588 Sonnenburg JL, et al. Gut microbes promote colonic serotonin production through an
- effect of short-chain fatty acids on enterochromaffin cells. Faseb j 2015;29:1395-403.
- 590 [43] Jin CJ, Engstler AJ, Sellmann C, Ziegenhardt D, Landmann M, Kanuri G, et al.
- 591 Sodium butyrate protects mice from the development of the early signs of

592 non-alcoholic fatty liver disease: role of melatonin and lipid peroxidation. Br J Nutr

593 2016:1-12.

- [44] Li J, Li RX, Liu G, Lv CF, Mi YL, Zhang CQ. Effect of melatonin on renewal of
- chicken small intestinal mucosa. Poult Sci 2017;96:2942-9.
- [45] Jeffery IB, O'Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, et al. An
- 597 irritable bowel syndrome subtype defined by species-specific alterations in faecal
- 598 microbiota. Gut 2012;61:997-1006.
- [46] Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, et al.
- 600 Functional dysbiosis within the gut microbiota of patients with constipated-irritable
- 601 bowel syndrome. Aliment Pharmacol Ther 2012;35:828-38.
- [47] Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC.
- Functional bowel disorders. Gastroenterology 2006;130:1480-91.
- [48] Liu Y, Zhang L, Wang X, Wang Z, Zhang J, Jiang R, et al. Similar Fecal
- 605 Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel
- 606 Syndrome and Patients With Depression. Clin Gastroenterol Hepatol
- 607 2016;14:1602-11 e5.
- [49] Zhang J, Song L, Wang Y, Liu C, Zhang L, Zhu S, et al. Beneficial effect of
- 609 butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats.
- 610 J Gastroenterol Hepatol 2019;34:1368-76.
- [50] Wang Y, Song F, Zhu J, Zhang S, Yang Y, Chen T, et al. GSA: Genome
- 612 Sequence Archive<sup/>. Genomics Proteomics Bioinformatics 2017;15:14-8.
- [51] Members BIGDC. Database Resources of the BIG Data Center in 2019. Nucleic
- 614 Acids Res 2019;47:D8-D14.
- 615
- 616

617 Figure legends

### 618 Figure 1 Increased melatonin expression was negatively associated with visceral

- 619 hypersensitivity in IBS-D patients.
- 620



621 622



- 624 = 28) (**A**, **D**) and patients with IBS-D (N = 32) (**B**, **E**) at x 400 magnification. As
- shown in **C** and **F**, the densities of melatonin cells and AANAT cells were

626 significantly higher in IBS-D patients than in healthy controls. The line in the scatter

- 627 plots (**C**, **F**) indicates the mean value. Melatonin cell density was negatively
- associated with visceral hypersensitivity in IBS-D patients (G, H, I, J). \*  $0.01 < P \le$
- 629 0.05. AANAT: arylalkylamine N-acetyltransferase; IBS-D: diarrhea-predominant IBS;

630 HC: healthy controls.

- 631
- 632

Figure 2 Increases in mast cells positively correlated with visceral hypersensitivity of IBS-D patients. 



Immunohistochemical staining of mast cells in the colon of HCs (N = 26) (A) and patients with IBS-D (N = 29) (B) at x 400 magnification. The densities of mast cells were significantly higher in IBS-D patients than in HC (C). Mast cell counts were positively correlated with visceral hypersensitivity in IBS-D patients (D, E, F, G). The line in the scatter plots (C) indicates the mean value. IBS-D: diarrhea-predominant IBS; HC: healthy controls. \*\*\*\*  $P \le 0.0001$ 

#### **Figure 3 Melatonin expression in fecal microbiota transplantation (FMT) rats.**

- 655 Immunohistochemical staining of melatonin in the colon of the GN group (A), GH
- group (**B**), and GI group (**C**) at x 400 magnification. As shown in (**D**), the density of
- melatonin cells was significantly higher in the GI group than in the GH and GN
- groups. The line in the scatter plots indicates the mean value. \*  $0.01 < P \le 0.05$ , \*\*
- 659  $0.001 < P \le 0.01$ . GI, Germ-free rats received fecal microbiota transplantation
- obtained from one IBS patient; GH, Germ-free rats received fecal microbiota
- transplantation obtained from one healthy control. GN, Germ-free without FMT.



666

662 663

664

665

- 667
- 668



669 Figure 4 Gut dysbiosis in IBS-D patients.



A. Partial least squares-discriminant analysis (PLS-DA) revealed separation in microbial composition between patients with IBS-D and HC. **B**. The abundance of *Firmicutes* was increased, and the abundance of *Bacteroidetes* was reduced in IBS-D patients compared with HC. **C**, **D**. Wilcoxon rank-sum test revealed that the abundance of *Prevotella\_9* was significantly increased in IBS-D patients at the genus and species levels. **E**. Manhattan plots showing enriched and reduced OTUs in IBS-D patients. OTUs that are significantly enriched are depicted as full triangles. The

dashed line indicates the threshold of significance (P = 0.05). The color and size of

each dot represents the different taxonomic affiliation of the OTUs and relative

abundance, respectively (genus level). \*  $0.01 < P \le 0.05$ . IBS-D:

- diarrhea-predominant IBS; HC: healthy controls.
- 682
- 683
- 684 685
- 686
- 687
- 688







690

groups.

A. Principal coordinates analysis (PCoA) indicated significant differences in 692 microbial composition between the GI group and GH group. **B.** The abundance of 693 694 Firmicutes was increased, and the abundance of Bacteroidetes was reduced in the GI group based on a community bar plot. C, D. Wilcoxon rank-sum test revealed that the 695 abundances of *Faecalibacterium*, *Roseburia*, and *Ruminococcus* were significantly 696 increased and that the abundance of Bacteroides was significantly reduced in the GI 697 group. E. Manhattan plots showing enriched and reduced OTUs in the GI group. 698 OTUs that are significantly enriched are depicted as full triangles. The dashed line 699 indicates the threshold of significance (P = 0.05). The color and size of each dot 700 represent the different taxonomic affiliation of the OTUs and relative abundance, 701 respectively (genus level). \*  $0.01 < P \le 0.05$ , \*\*  $0.001 < P \le 0.01$ . GH, Germ-free rats 702 received fecal microbiota transplantation obtained from one healthy control. GI, 703 704 Germ-free rats received fecal microbiota transplantation obtained from one IBS patient. 705 706

- 707
- 708

#### 709 Figure 6 Relationship between melatonin and gut microbiota in humans.



710

A. Heat maps of Spearman's rank correlation coefficients between human colonic 711 mucosal melatonin and AANAT expression, SCFAs and gut microbiota at the species 712 level. Roseburia was significantly positively correlated with melatonin and AANAT 713 expression. Lachnospira and Parasutterella were significantly positively associated 714 with AANAT expression. Roseburia and Lachnospira were significantly positively 715 related to fecal butyrate. B. The relationship between melatonin and gut microbiota in 716 FMT rats. Heat maps of Spearman's rank correlation coefficients between FMT rat 717 colonic mucosal melatonin expression and gut microbiota at the species level. 718 Roseburia, Lachnospiraceae, Blautia and Ruminiclostridium species, which belong to 719 *Clostridium* cluster XIVa, were significantly positively related to melatonin 720

721 expression. \*  $0.01 < P \le 0.05$ , \*\*  $0.001 < P \le 0.01$ , \*\*\*  $P \le 0.001$ .





Levels of melatonin in the supernatants were detected using ELISA. AANAT

expression was detected with western blot assays. A. Treatment with sodium butyrate

significantly increased melatonin secretion in a dose-dependent manner. **B**. Relative

728 AANAT quantification by western blot analysis of protein extract of control or

sodium butyrate-treated BON-1 cells. The results are presented as the mean  $\pm$  SEM. \*

 $0.01 < P \le 0.05$ . AANAT: arylalkylamine N-acetyltransferase

. . .

# 747 Table 1 Demographic and clinical features of patients with IBS-D and HC

	IBS-D	НС	P value
Number of subjects	32	28	
Age (years)	32 ±1.77	$30 \pm 1.56$	0.471
Gender (male:female)	28:4	20:8	0.219
BMI (kg/m2)	$22.6 \pm 0.62$	$23.1 \pm 0.73$	0.564
*Hospital anxiety scale	$5.41 \pm 0.60$	$3.90\pm\!0.79$	0.127
*Hospital depression scale	$4.28 \pm 0.47$	$2.75 \pm 0.65$	0.056
<sup>#</sup> Rectal distension (mmHg)			
First sensation	$9.07 \pm 0.60$	$11.14 \pm 0.88$	0.055
Sensation of defecation	$16.50 \pm 1.00$	$20.29 \pm 1.71$	0.049
Sensation of urge to defecation	$24.64 \pm 1.40$	$29.14 \pm 2.35$	0.089
Maximally tolerable distension	34.81 ±1.65	39.11 ±2.37	0.132
IBS-SSS	$186.83 \pm 8.42$		

*Note:* The data are presented as mean ± s.e. IBS-SSS: IBS Symptom Severity Scale;
IBS-D: diarrhea-predominant IBS; HC: healthy control. \*: Numbers of subjects:
IBS-D 26, HC 17; \*: Numbers of subjects: IBS-D 28, HC 17.

# 768 Table 2 Correlations between colonic mucosal melatonin cell density with clinical

## 769 parameters in human

	Melatonin cell density [r (P values)]		
	IBS-D	НС	
Psychological feature			
*Hospital anxiety scale	0.207(0.310)	-0.372(0.141)	
*Hospital depression scale	0.007(0.972)	-0.414(0.099)	
<sup>#</sup> Rectal distension (mmHg)			
First sensation	0.242(0.216)	-0.619 (0.018)	
Sensation of defecation	0.337(0.080)	-0.662 (0.010)	
Sensation of urge to defecation	0.519 (0.005)	-0.521(0.056)	
Maximally tolerable distension	0.432(0.024)	-0.373(0.140)	
IBS-SSS scores	0.068(0.720)		

*Note:* Spearman's correlation coefficients are shown as *P* values in parentheses.

771 IBS-D: diarrhea-predominant IBS; HC: healthy control. IBS-SSS: IBS Symptom

772 Severity Scale; \*: Numbers of subjects: IBS-D 26, HC 17; <sup>#</sup>Numbers of subjects:

773 IBS-D 28, HC 17.